3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
3
Sarcoma
2
Triple Negative Breast Neoplasms
1
Sarcoma, Ewing
1
Recurrence
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasm Metastasis
1
Her-2 Negative Breast Cancer
1
Fludzoparib" and Anti-angiogenic
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Breast Cancer Metastatic
1
Advanced Solid Tumors
1
Interventions
Magnetic Resonance Spectroscopy
51
Specimen Handling
42
enzalutamide
36
Androgen Antagonists
35
Radiosurgery
33
Radiotherapy
31
darolutamide
26
Prednisone
26
Abiraterone Acetate
25
Leuprolide
22
Docetaxel
22
apalutamide
21
abiraterone
19
Pluvicto
19
Standard of Care
18
Triptorelin Pamoate
17
Radiation
17
Biopsy
16
relugolix
15
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
15
Goserelin
14
Blood Specimen Collection
13
gallium 68 PSMA-11
12
X-Rays
11
Surveys and Questionnaires
11
pembrolizumab
10
luprolide acetate gel depot
10
Carboplatin
10
Methods
9
Interviews as Topic
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Prostatic Neoplasms
×
fluzoparib
×
Clear all
NCT06971211
2025-05-14
PARTOM
First Hospital of China Medical University
Phase 2
Recruiting
40 enrolled